Moderna (MRNA) Assets (2017 - 2026)

Moderna (MRNA) has 10 years of Assets data on file, last reported at $11.5 billion in Q1 2026.

• On a quarterly basis, Assets fell 9.57% year-over-year to $11.5 billion in Q1 2026; TTM through Mar 2026 was $11.5 billion, a 9.57% decrease from a year earlier, with the FY2025 full-year figure at $12.3 billion, down 12.76% from the prior year.
• Assets for Q1 2026 stood at $11.5 billion, down from $12.3 billion in the prior quarter.
• Over the last five years, Assets for MRNA reached as high as $27.6 billion in Q1 2022 and fell as low as $11.5 billion in Q1 2026.
• Historically, Assets has averaged $18.4 billion across 5 years, with a median of $16.7 billion in 2024.
• Across the five-year window, Assets soared 117.5% in 2022 and plunged 30.66% in 2024, its largest moves.
• Year by year, Assets stood at $25.9 billion in 2022, then declined by 28.74% to $18.4 billion in 2023, then slipped by 23.25% to $14.1 billion in 2024, then declined by 12.76% to $12.3 billion in 2025, then slipped by 6.89% to $11.5 billion in 2026.
• Per Business Quant data, the three most recent Assets figures were $11.5 billion in Q1 2026, $12.3 billion in Q4 2025, and $12.1 billion in Q3 2025.